RefleXion Medical Stock
Biologically-Guided Radiotherapy Systems for Patients with Cancer
Sign up today and learn more about RefleXion Medical Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About RefleXion Medical Stock
RefleXion Medical is a privately held medical device company developing the first biology-guided radiation therapy system for cancer treatment. By leveraging Positron Emission Tomography (PET) in a novel way, RefleXion's patented technology will allow tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. Early validation of RefleXion's technology was funded by the National Cancer Institute. RefleXion is backed by premier investors; Sofinnova Partners, KCK, Pfizer, Venrock and Johnson & Johnson Innovation.
Investors
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Venrock
Devoted Health, Zenefits, TAE Technologies, Dollar Shave Club, Lucid Motors, Dataminr, 6sense, AppNexus, Salsify, Astranis
Johnson & Johnson Innovation
GT Healthcare Capital Partners
Funding History
| April 2014 | $11.7M |
|---|---|
| April 2016 | $52.1M |
| March 2018 | $103M |
| April 2020 | $125M |
Management
Chief Executive Officer
Todd Powell
Chief Financial Officer
Martyn Webster
Chief Technology Officer
Sam Mazin
Press
finance - Apr, 6 2024
CMS Assigns Accretive Reimbursement for RefleXion's Breakthrough SCINTIX Therapylinkedin - Apr, 6 2024
Heath Skinner on LinkedIn: #radonc #radiation #clinicaltrials #radiotracers | 12 commentsmassdevice - Apr, 6 2024
RefleXion inks AI partnership for cancer treatment planningbusinesswire - Apr, 6 2024
RefleXion and Limbus AI Announce Technology Integration to Expedite Cancer Treatment Planningbusinesswire - Dec, 19 2023
RefleXion Showcases Breakthrough SCINTIX Biology-Guided ...EquityZen Recognized As:
